ClinicalTrials.gg
Active, not recruitingNCT03819465MAGELLANUpdated May 12, 2026

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

A Phase 1 interventional study of Durvalumab and Danvatirsen in Metastatic Non-Small Cell Lung Cancer (NSCLC), sponsored by AstraZeneca. Active, not recruiting at 41 sites in 9 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
28th of 94
175 · median 74
Started
2018
with 7 others
Phase 1
13 of 94
1 open now
Primary completion
2023-05
later than 7 of 36 live
Registered
38th of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 28th largest by enrollment, is one of 8 that started in 2018, is one of 13 in phase 1, reaches primary completion later than 7 of the 36 other live ones, and was the 38th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)

Read the detailed description

This is a Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC).

03

Conditions studied

  • Metastatic Non-Small Cell Lung Cancer (NSCLC)

Keywords

  • First-Line Stage IV Metastatic Non-Small Cell Lung Cancer
  • Stage IV Metastatic Non-Small Cell Lung Cancer
  • Metastatic Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer
  • Non-Small Cell Lung
  • Non-Small Cell
  • NSCLC
  • Non-Small Cell Lung Carcinoma
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation
  • No prior chemotherapy or any other systemic therapy for NSCLC
  • Prior platinum-containing adjuvant, , or definitive chemoradiation for advanced disease are eligible, if progression has occurred >12 months from end of last therapy
  • Known tumor status
  • Tumors that lack activating EGFR mutations and ALK fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in per local standard of care
  • status at 0 or 1 at enrollment
  • of at least 12 weeks
  • Troponin I or T ≤ (per institutional guidelines)

Exclusion criteria

Exclusion Criteria:

  • Active or prior documented or inflammatory disorders
  • History of active primary immunodeficiency
  • Any prior chemotherapy or any other systemic therapy for NSCLC
  • Untreated
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    A1

    Durvalumab

    Drug: Durvalumab

  • Experimental
    A2

    Durvalumab + danvatirsen

    Drug: Durvalumab · Drug: Danvatirsen

  • Experimental
    A3

    Durvalumab + oleclumab

    Drug: Durvalumab · Drug: Oleclumab

  • Experimental
    A4

    MEDI5752

    Drug: MEDI5752

  • Experimental
    B1

    Durvalumab + Investigator's choice of chemotherapy

    Drug: Durvalumab · Drug: Pemetrexed · Drug: Carboplatin · Drug: Gemcitabine · Drug: Cisplatin · Drug: Nab-paclitaxel

  • Experimental
    B2

    Durvalumab + Investigator's choice of chemotherapy + danvatirsen

    Drug: Durvalumab · Drug: Danvatirsen · Drug: Pemetrexed · Drug: Carboplatin · Drug: Gemcitabine · Drug: Cisplatin · Drug: Nab-paclitaxel

  • Experimental
    B3

    Durvalumab + investigator's choice of chemotherapy + oleclumab

    Drug: Durvalumab · Drug: Oleclumab · Drug: Pemetrexed · Drug: Carboplatin · Drug: Gemcitabine · Drug: Cisplatin · Drug: Nab-paclitaxel

  • Experimental
    B4

    MEDI5752

    Drug: MEDI5752

  • Experimental
    A5

    AZD2936

    Drug: AZD2936

  • Experimental
    B5

    AZD2936 + chemotherapy

    Drug: Pemetrexed · Drug: Carboplatin · Drug: Cisplatin · Drug: AZD2936

Interventions

  • Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1

    Also known as: MEDI4736

  • Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8

    Also known as: AZD9150

  • Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1

    Also known as: MEDI9447

  • MEDI5752 IV Every 3 weeks (q3w)

  • Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study

  • Carboplatin IV Day 1 of each 21-day cycle

  • Gemcitabine IV Days 1 and 8 of each 21-day cycle

  • Cisplatin IV Day 1 of each 21-day cycle

  • Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle

  • AZD2936 IV

06

What researchers measure

Primary outcomes

  1. Assessment of AEs by CTCAE v5.0

    Assessment of safety and tolerability of each treatment arm

    Time frame: From informed consent until the safety follow-up visit 3 months after the last dose of study drug, or until the final data cut-off (DCO) date, whichever is earlier.

Secondary outcomes

  1. Objective Response Rate (ORR)

    Assessment of the efficacy of each treatment arm according to RECIST 1.1. ORR: The percentage of evaluable patients with a confirmed Investigator-assessed visit response of CR or PR

    Time frame: Tumor assessments every 6-9 weeks until week 48-54, then every 12 or 18 weeks, depending on treatment arm until the earliest of radiological progression, death, withdrawal of consent, or final DCO (approximately 4 months after last patient randomized).

  2. Duration of Response (DoR)

    Assessment of the efficacy of each treatment arm according to RECIST 1.1. DoR: Time from date of first detection of objective response until the date of objective radiological disease progression

    Time frame: Tumor assessments every 6-9 weeks until week 48-54, then every 12 or 18 weeks, depending on treatment arm until the earliest of radiological progression, death, withdrawal of consent, or final DCO (approximately 4 months after last patient randomized).

  3. Progression Free Survival (PFS)

    Assessment of the efficacy of each treatment arm according to RECIST 1.1. PFS: Time from date of treatment assignment until the date of objective radiological disease progression using RECIST 1.1 or death (by any cause in the absence of progression)

    Time frame: Tumor assessments every 6-9 weeks until week 48-54, then every 12/18 weeks based on arm until progression, death, withdrawal or final DCO. Further PFS data will be collected until 6 months after last patient dosed or final DCO

  4. Overall Survival (OS)

    OS: Time from date of treatment assignment until the date of death by any cause

    Time frame: OS data will be collected until death, 6 months after last patient dosed, or the final DCO date, whichever is earlier.

  5. Blood concentration of durvalumab and novel oncology therapies

    Drug concentration of durvalumab and novel oncology therapies

    Time frame: From Cycle 1 Day 1 until Cycle 6/7 Day 1 (21-28-day cycles) depending on arm, then every 3 cycles (except for Arms A5 & B5), at end of treatment (Arms A4 & B4, A5 & B5 only), and until 3 months following treatment discontinuation, or the final DCO date.

  6. Frequency of anti-drug antibodies (ADAs) for durvalumab and applicable novel oncology therapies

    Investigation of the immunogenicity of durvalumab and each applicable novel oncology therapy in all applicable treatment arms

    Time frame: From Cycle 1 Day 1 until Cycle 6/7 Day 1 (21-28-day cycles) depending on arm, then every 3 or 6 cycles (except for arms A5&B5), at end of treatment (arms A4&B4, A5&B5 only), until 3/6 months after treatment discontinuation, or the final DCO date.

07

Study locations

41 sites
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Vienna, 1140, Austria
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Bialystok, 15-027, Poland
  • Research Site
    Bydgoszcz, 85-796, Poland
  • Research Site
    Gdansk, 80-214, Poland
  • Research Site
    Grudziądz, 86-300, Poland
  • Research Site
    Lodz, 90-302, Poland
  • Research Site
    Olsztyn, 10-357, Poland
  • Research Site
    Tomaszów Mazowiecki, 97-200, Poland
  • Research Site
    Warsaw, 02-781, Poland
  • Research Site
    Wroclaw, 53-413, Poland
  • Research Site
    Krasnoyarsk, 660133, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Saint Petersburg, 191014, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Cheongju-si, 28644, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Seoul, 110-744, South Korea
  • Research Site
    Barcelona, 08025, Spain
  • Research Site
    Barcelona, 8003, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Kaohsiung City, 807, Taiwan
  • Research Site
    Taichung, 402, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Tainan, 70403, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 112, Taiwan
  • Research Site
    Taipei, 235, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Bangkok, 10330, Thailand
  • Research Site
    Bangkok, 10700, Thailand
  • Research Site
    Chiang Mai, 50200, Thailand
  • Research Site
    Hat Yai, 90110, Thailand
08

References and documents

Publications

  • Cho BC, Charoentum C, Kim DW, Yang CT, Dziadziuszko R, Geater SL, Mann H, Afshar-Imani B, Lyfar P, Yang JC, Patel SP. MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naive metastatic non-small-cell lung cancer. Lung Cancer. 2026 Jan;211:108834. doi: 10.1016/j.lungcan.2025.108834. Epub 2025 Nov 7. PubMed 41380462 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in May 2023, 52 months.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 52 months is close to that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2018
First posted
Jan 28, 2019
StartActual
Dec 27, 2018
Primary completionActual
May 23, 2023
CompletionEst.
Jul 1, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03819465
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 28, 2019
Start date
Dec 27, 2018
Primary completion
May 23, 2023
Completion
Jul 1, 2026 (estimated)
Last update
May 12, 2026

Study contacts

Sandip Patel, MD
principal investigator · UCSD Morres Cancer Center
Chih-Hsin Yang, MD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Volrustomig · Pemetrexed · Carboplatin · Cisplatin · Rilvegostomig

Start the discussion